tbuckley/cabot-search huggingface dataset:
The Oral Mtor Inhibitor Everolimus in Relapsed and Refractory Hodgkin Lymphoma- Compassionate Use in 8 Centers in Brazil
Authors: Talita Silveira Da Rocha, Sergio Costa Fortier, Nelson Siqueira de Castro, Marcia T Delamain, José Salvador Oliveira, Guilherme Perini, Valeria Buccheri, Rafael Dezen Gaiolla, Laura Fogliato, Andressa Laranja, Maeva Pinto, Carlos Chiattone
Journal: Blood (2015)
PDCT-02. MARKED RECOVERY OF VISION IN A CHILD WITH OPTIC PATHWAY GLIOMA TREATED UPFRONT WITH BEVACIZUMAB AND VINBLASTINE
Authors: Magimairajan Issai Vanan, Colin Kazina, Ian Clark, Sherry Krawitz, Martin Bunge
Journal: Neuro-Oncology (2016)

Optic Pathway Gliomas (OPGs) are relatively rare and account for up to 5% of brain tumors in children. They are low grade neoplasms (WHO grade I-II), can originate from any location along the visual system (nerve, chiasm, tract or radiation) and can be sporadic or associated with Neurofibromatosis-1 (NF-1). Visual complaints are the major presenting symptoms and include visual acquity (VA) / visual field (VF) defects, Nystagmus and Proptosis. Standard front line therapy (Vincristine/ Carboplatin) produces mild improvement in VA in one third of the patients. Bevacizumab, an anti-angiogenic agent that targets vascular endothelial growth factor has been shown to help in recovery of vision in children with OPGs. We report a case of a sporadic Left optic pathway (nerve/chiasm) glioma treated upfront with Bevacizumab and Vinblastine resulting in significant and sustained recovery of vision. Our patient presented to us with a rapidly increasing lesion arising from the left intracranial optic nerve / chiasm with significant mass effect and peripheral contrast enhancement on serial follow up imaging (MRI). Ophthalmological exam revealed VA of 6/150 (was 6/12) and a 2+ afferent pupillary defect in the left eye. Biopsy of the lesion revealed Pilocytic astrocytoma (WHO Grade-I) which was negative for BRAF (V600E mutation and fusion defects). He is being treated with Weekly IV Vinblastine (6mg/m2) for a total of 68 weeks and IV Bevacizumab (10mg/kg) every two weeks for the initial 24 weeks. He has tolerated the treatment very well except for neutropenia (requiring dose reduction in Vinblastine). His visual assessment at 6months shows VA of 6/38 (left eye) and MRI shows > 50% reduction in the size of the lesion. Our case and case reports in literature suggesting recovery of vision in OPGs warrants incorporation of Bevacizumab in prospective randomized clinical trials for the treatment of chemotherapy naïve children with OPGs.
Subconjunctival injectable dendrimer-dexamethasone gel for the treatment of corneal inflammation
Authors: Uri Soiberman, Siva P. Kambhampati, Tony Wu, Manoj K. Mishra, Yumin Oh, Rishi Sharma, Jiangxia Wang, Abdul Elah Al Towerki, Samuel Yiu, Walter J. Stark, Rangaramanujam M. Kannan
Journal: Biomaterials (2017)
An Integrative Analysis of Network Motifs and Gene Expression Data to Discover Experimentally Testable Transcription Factor-miRNA-Gene Regulatory Loops In Multiple Myeloma
Authors: Samir B. Amin, Zhenyu Yan, Parantu Shah, Jesús F. San Miguel, Stephane Minvielle, Hervé Avet-Loiseau, Kenneth C. Anderson, Nikhil C. Munshi, Cheng Li
Journal: Blood (2010)
Observational study of the cetuximab relative dose intensity (RDI) in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Data on the maintenance and every two weeks use (DIRECT study)
Authors: J. Guigay, E. Chamorey, P. Céruse, F. Mornex, M. Degardin, M. Alfonsi, L. Digue, A. Berrier, X. Artignan, L. Cals, S. Faivre, E. Vuillemin, F. Rolland, A. Timochenko, E. Babin, A. Seronde-Delmas, A. Prevost, O. Romano, F. Peyrade, C. Le Tourneau
Journal: Annals of Oncology (2016)
Blocking TNF and IL-1 Sensitizes AML Stem Cells to NF-κB Inhibitor Treatment
Authors: Volk Andrew, Jing Li, Jun Zhang, Joseph Cannova, Caiqin Hao, Chenglong Hu, Jiewen Sun, Yan Xu, Wei Wei, Peter Breslin, Jianjun Chen, Jiwang Zhang
Journal: Blood (2014)
Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results
Authors: M.B. Atkins, E.R. Plimack, I. Puzanov, M.N. Fishman, D. McDermott, D.C. Cho, U. Vaishampayan, S. George, T. Olencki, J. Tarazi, B. Rosbrook, K. Fernandez, S. Keefe, T. Choueiri
Journal: Annals of Oncology (2016)
BMET-38. PROSTATIC CARCINOMA METASTATIC TO THE NERVOUS SYSTEM: PARENCHYMAL AND PROBLEMATIC CASES
Authors: David Ormond, BK DeMasters
Journal: Neuro-Oncology (2016)

Demographics of metastatic disease coming to biopsy or surgical resection in the nervous system have changed dramatically over the years, due to the advent of treatment with non-interventional techniques such as stereotactic radiosurgery. Patients with known metastatic nervous system involvement, especially if multifocal, are most likely to be treated without histological confirmation, changing which cases are most likely to come to neurosurgical attention. Namely, single metastases of unknown origin, single presumed metastases in patients with known previous diagnosis of malignancy(s) from tumors which seldom spread to the nervous system, and dural/epidural masses requiring emergent spinal decompression are more likely to prompt surgical intervention. Metastatic prostatic carcinoma is encompassed in the two latter categories. We reviewed our databases for all cases in which metastatic prostatic carcinoma was strongly clinically suspected and/ or diagnosed at biopsy, 2000-present. As expected 16 cases were dural-based tumors, but 5 were intraparenchymal in pituitary region, right frontal and occipital lobes, cerebellum, right temporal lobe and right thalamus. The latter has been reported only rarely. Conversely, patients with known histories of prostatic carcinoma and suspected metastases were identified having neurocytoma, skull base chordoma, ectopic pituitary adenoma to clival region (detailed in Clin Neuropathol. 2012;31(1):24-30), anaplastic meningioma, and undifferentiated malignancies. Two more presented morphologically-challenging diagnoses, including a small cell neuroendocrine variant of prostatic carcinoma and one extremely poorly differentiated with loss of several diagnostic immunohistochemical markers. We conclude that metastatic prostatic carcinoma to the nervous system continues to provide pre-biopsy diagnostic challenges in modern day practice, due to the mixed dural and parenchymal involvement that can be seen, coupled with the frequency with which a diagnosis of previous prostatic carcinoma has been rendered in a patient presenting with new intracranial and/or dural mass(es). Our cohort suggests that intraparenchymal prostatic metastases are likely more frequent than cited incidences.
Daratumumab in Combination with Lenalidomide Plus Dexamethasone Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX)
Authors: Christopher Chiu, Tineke Casneuf, Amy Axel, Andrew Lysaght, Jaime Bald, Nushmia Z Khokhar, Torben Plesner, Saad Z Usmani, Hartmut Goldschmidt, Tahamtan Ahmadi, Kenneth Chan, A. Kate Sasser
Journal: Blood (2016)
Flamsa-RIC Sequential Regimen in High Risk CR1 AML Patients: Preliminary Results From a Pilot Study
Authors: Marie Y. Detrait, Mohamad Sobh, Xavier Thomas, Verane Schwiertz, Florence Ranchon, Sandrine Hayette, Isabelle Tigaud, Franck E. Nicolini, Fiorenza Barraco, Sophie Ducastelle, Youcef Chelghoum, Hélène Labussière-Wallet, Adrien Quintela, Nathalie Tedone, Sothiny Sar, Valérie Chapelle, Stéphane Morisset, Jean-Pierre Magaud, Catherine Rioufol, Mauricette Michallet
Journal: Blood (2012)
STMC-05. NEURAL STEM CELLS AND GLIOBLASTOMA
Authors: Rossella Rispoli, Alessandro di Chirico, Alessandro Ciampini, Anna Kouleridou, Nevia Caputo, Sandro Carletti
Journal: Neuro-Oncology (2016)

Glioblastoma multiforme represents one of the most frequent brain cancers, it display a rather heterogeneous cellular composition, as indicated by the term “multiforme”. Recently some authors have described the isolation and identification of cancer neural stem cells from human adult glioblastoma multiforme, which possess the capacity to establish, sustain, and expand these tumors, even under the challenging settings posed by serial transplantation experiments. Our study focused attention on the distribution of neural cancer stem cells inside the tumour; the study ID divided in three phases: -removal of tumoural specimens in different tumour’s zone (centre (C), periphery(P), marginal zone(MZ)) in an operative room integrated with 1.5 T scanner; -isolation, characterization of neural cancer stem cells from human adult glioblastoma multiforme; -identification the distribution of neural cancer stem cells inside the tumour. We have showed that C, P and Mz cells formed neuro spheres; at the third passage MZ cells didin’t proliferate and differentiated. P and C cells didn’t differentiated and C cells expressed the highest percentage of CD133; P cells could be the real NCSC. The study presents some limits: few case studied; it remains unclear whether tumor neural stem cells in glioblastomas multiforme derive from the transformation of normal human neural stem cells or whether their presence therein reflects the result of the transformation and de-differentiation of a more mature brain cell, which brought about otherwise silent/latent stem cell properties.
Very Late Antigen-4 (VLA-4) Expression by AML Blasts: Correlation of VCAM-1 Binding to Overall Survival.
Authors: Pamela S. Becker, Thalia Papayannopoulou, Kenneth J. Kopecky, Adrianne N. Hanks, John M. Harlan, Cheryl L. Willman, Frederick R. Appelbaum
Journal: Blood (2005)
Association of PTEN loss and local recurrence in stage II-III colon cancer.
Authors: Z. Jiang, T. R. Mehta, Y. N. You, G. J. Chang, C. Eng, M. J. Overman, D. Maru, S. R. Hamilton, S. Kopetz
Journal: Journal of Clinical Oncology (2011)

399 Background: Activation of the PI3K/Akt signaling pathway by PIK3CA mutations has been associated with increased risk for local recurrence (LR) in rectal cancer patients (pts). We hypothesized that loss of expression of PTEN, a tumor suppressor gene and negative regulator of the PI3K/Akt pathway, may also be associated with increased rates of LR in colon cancer. Methods: We studied 156 pts with stage II-III colon cancer resected from 1/1990 to 12/2002, including pathology review, PTEN immunohistochemistry, microsatellite instability (MSI) status, 18q loss of heterozygosity (LOH) status and clinical follow-up. PTEN expression with a CLIA-compliant protocol (DAKO antibody) was determined in a tissue microarray with four cores from each tumor and with non-neoplastic mucosa. PTEN loss was defined as complete absence of expression in malignant epithelium with preserved expression of adjoining non-neoplastic tissue serving as a positive control. LR was defined as anastomotic or pericolic peritoneal disease. Results: 83 M and 73 F pts with median age of 63 were included, with median follow-up of 7.6 yrs. PTEN loss was identified in 26 (16.7%) pts. There were no significant differences in age, sex, T stage, N stage, tumor differentiation, tumor site, lymphovascular invasion (LVI), mucinous component, MSI status or 18q LOH between the PTEN-lost and PTEN-intact groups. The overall survival, relapse-free survival, and distant metastases rate were similar. However, PTEN loss was associated with higher rates of LR (15.4% vs. 4.6%, p = 0.041), and the time to LR was shorter for pts with PTEN loss in their tumor than in PTEN-intact pts (HR 3.3, p = 0.049 by log-rank). LR was associated with LVI, R-sided tumor, 18qLOH, and PTEN loss in univariate analysis. In a multivariate analysis, PTEN loss was associated with a 10.6 fold increased risk of LR (95% CI: 1.7-64.8, p = 0.011). Conclusions: PTEN loss is associated with a higher rate of and shorter time to LR after resection of colon cancer. This result is consistent with a prior report on the role of PI3K pathway in LR of rectal cancer and suggests that PTEN alteration is a prognostic indicator and that the PI3K/Akt pathway is a potential therapeutic target for these pts. No significant financial relationships to disclose.
Molecular Remission in MLL/AF4-Positive Infant Leukemia Treated with the All Trans-Retinoic Acid Based MLL-Baby Protocol.
Authors: Grigory Tsaur, Elizaveta Semenikhina, Anna Ivanova, Tatiana Nasedkina, Alexander Popov, Egor Shorikov, Leonid Saveliev, Larisa Fechina
Journal: Blood (2007)
Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the phase 3 DECISION trial: An exploratory crossover adjustment analyses
Authors: M. Brose, B. Jarzab, R. Elisei, L. Giannetta, L. Bastholt, Cdela Fouchardiere, F. Pacini, R. Paschke, C. Nutting, Y.K. Shong, S. Sherman, J. Smit, J. Chung, G. Meinhardt, M. Schlumberger, C. Kappeler
Journal: Annals of Oncology (2016)
NIMG-30. DIAGNOSTIC PERFORMANCE OF 18-FLUDEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY (FDG-PET) IN EVALUATION OF GLIOMA
Authors: Benjamin Chua, Lindy Jeffree, Paul Thomas, Steven Goodman, Zarnie Lwin
Journal: Neuro-Oncology (2016)

FDG-PET is a widely available imaging modality for extracranial malignancy. In gliomas, novel amino acid tracers have been developed with superior signal-to-background ratio, but are hampered by limited availability, lack of experience and poor correlation between tracer uptake and glioma grade. We sought to quantify the utility of FDG-PET, alone and in combination with MRI, in identifying high-grade regions of suspected or known gliomas. A retrospective review was conducted of patients who had an FDG-PET performed at our institution as part of the diagnostic workup of suspected low-grade glioma, or in follow-up of known glioma with suspected progressive or recurrent disease. MRI findings preceding the FDG-PET were collected, as were treatment data, histology and survival outcomes. Sensitivity, specificity, positive and negative predictive values (PPV, NPV) were calculated for identification of high-grade histology (WHO III or IV, or metastatic disease) obtained post PET. 49 patients underwent 56 FDG-PET scans; 18 in the diagnostic setting, and 36 in follow-up with known diagnosis of glioma. 43 patients had histology obtained at a median of 68 days post FDG-PET; all but one had a prior MRI with gadolinium. In identification of high-grade histology, abnormal FDG uptake on PET demonstrated sensitivity of 59% and specificity of 80%, PPV of 84% and NPV of 52%. When PET and MRI were concordantly positive (FDG uptake with MRI contrast enhancement), specificity of 91% and PPV of 93% were achieved. FDG-PET has high specificity in identification of high-grade histology. The combination of MRI and FDG-PET have utility in impacting treatment by identifying potential high-grade regions for biopsy or resection. Due to limited sensitivity and NPV, a negative FDG-PET result, alone or in combination with MRI, should not guide a decision for observation where surgery would otherwise be recommended.
Liver fibrosis scores predict liver disease mortality in the United States population
Authors: Aynur Unalp‐Arida, Constance E. Ruhl
Journal: Hepatology (2017)

Fatty liver disease is common in the United States and worldwide due to changing lifestyles and can progress to fibrosis and cirrhosis contributing to premature death. We examined whether liver fibrosis scores were associated with increased overall and disease‐specific mortality in a United States population–based prospective survey with up to 23 years of linked‐mortality data. Data were analyzed from 14,841 viral hepatitis–negative adult participants in the third National Health and Nutrition Examination Survey, 1988‐1994. Liver fibrosis was predicted using the aspartate aminotransferase–to‐platelet ratio index (APRI), fibrosis‐4 (FIB‐4) score, nonalcoholic fatty liver disease fibrosis score (NFS), and Forns score. Participants were passively followed for mortality, identified by death certificate underlying or contributing causes, by linkage to National Death Index records through 2011. Hazard ratios (HR) for mortality were calculated using Cox proportional hazards regression to adjust for mortality risk factors. During follow‐up, cumulative mortality was 28.0% from all causes and 0.82% with liver disease, including primary liver cancer. Elevated liver disease mortality was found with an intermediate to high APRI (HR, 9.44; 95% confidence interval [CI], 5.02‐17.73), intermediate (HR, 3.15; 95% CI, 1.33‐7.44) or high (HR, 25.14; 95% CI, 8.38‐75.40) FIB‐4 score, high NFS (HR, 6.52; 95% CI, 2.30‐18.50), and intermediate (HR, 3.58; 95% CI, 1.78‐7.18) or high (HR, 63.13; 95% CI, 22.16‐179.78) Forns score. Overall mortality was also greater with higher fibrosis scores. Conclusion: In the United States population, higher liver fibrosis scores were associated with increased liver disease and overall mortality. Liver health management with common clinical measures of fibrosis risk stratification merits further investigation. (H epatology 2017;66:84–95).
The role of the <i>KRAS</i> G13D mutation in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy plus cetuximab.
Authors: S. Tejpar, C. Bokemeyer, I. Celik, M. Schlichting, E. Van Cutsem
Journal: Journal of Clinical Oncology (2011)

630 Background: The CRYSTAL and OPUS studies showed that adding cetuximab (cet) to first-line chemotherapy (CT) significantly improved clinical benefit in patients (pts) with KRAS wild-type (wt) mCRC. Pts with KRAS codon 12 or 13 mutations are excluded from cet treatment. Studies suggest that not all KRAS mutations are equivalent in their biologic effects. Occasional responses and prolonged disease stabilization have been recorded following cet treatment of tumors with mainly KRAS codon 13 mutations. We investigated the influence of the most common KRAS codon 13 mutation (G13D) on clinical outcome compared with pts with other KRAS mutations or wt tumors in the CRYSTAL and OPUS trials. Methods: KRAS mutations were detected in tumor DNA from archival material using a PCR clamping and melting curve technique. Treatment arms were compared by KRAS mutation status for progression-free (PFS) and overall survival (OS). Results: In the CRYSTAL study of 1,063 evaluable pts 63% were KRAS wt, 6% were G13D mutant (mt) and 32% had other mutations. In the OPUS study of 315 evaluable pts, 57% were KRAS wt, 7% were G13D mt, and 36% had other mutations. Compared with KRAS wt pts those with G13D mutations did not benefit from the addition of cet to CT (Table). Data of comparisons of the G13D mutation with other KRAS mutations in these studies will be presented. Conclusions: Patients with KRAS G13D mt tumors did not appear to benefit from the addition of cet to first-line CT for mCRC. This analysis confirms the current practice of KRAS mutation testing as the standard diagnostic tool for determining first-line treatment of mCRC pts. [Table: see text] [Table: see text]
Erroneous Interpretation of Valid Experimental Observations Through Interference by the LDH Virus: Reply
Authors: Wayne L. Ryan
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Erroneous Interpretation of Valid Experimental Observations Through Interference by the LDH Virus: Reply Get access Wayne L. Ryan Wayne L. Ryan University of Nebraska Medical Center, Omaha, Nebraska 68105 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 52, Issue 5, May 1974, Page 1677, https://doi.org/10.1093/jnci/52.5.1677 Published: 01 May 1974
Acetaminophen in Pregnancy and Adverse Childhood Neurodevelopment
Authors: Per Damkier, Anthony R. Scialli, Shari I. Lusskin
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
IMST-48. PRIMING OF HOST T CELL MEMORY IS REQUIRED FOR THE EFFICACY OF ADOPTIVE CELL THERAPY
Authors: Catherine Flores, Rebecca Abraham, Duane Mitchell
Journal: Neuro-Oncology (2016)

Good clinical outcomes in response to adoptive cellular therapies are correlated with anti-tumor function, intratumoral migration, and persistence of adoptively transferred tumor-specific T cells. Our group has developed a highly efficacious adoptive cell therapy (ACT) against intracranial glioma that meets these criteria. Further evaluation of our adoptive cell therapy platform reveals that ACT also primes host-derived T cells, and our OBJECTIVE is to demonstrate that this phenomenon is required for efficacy of adoptive immunotherapy. We employ bone marrow-derived dendritic cells pulsed with tumor-derived RNA to ex vivo expand tumor-specific T lymphocytes (TTRNA-T cells). These cells are adoptively transferred into tumor bearing mice followed by dendritic cell vaccines. Tumor bearing mice receive lymphodepletive host conditioning and bone marrow rescue prior to adoptive transfer. Adoptive cell therapy with TTRNA-T cells is efficacious in up to 40% intracranial glioma bearing immunocompetent C57BL/6 hosts, but this efficacy is abrogated in both CD4 and CD8 depleted mice. In addition, no efficacy was observed when ACT was administered to tumor-bearing immunodeficient Rag 1-/- mice. In glioma bearing C57BL6 mice that receive ACT, host-derived T cells upregulate a memory phenotype. These host-derived CD8+ cells mount central memory, and CD4+ cells mount both central memory and effector phenotypes. Serial transfer of these host-derived T cells into naïve mice provided protective immunity against a tumor challenge. Secondary transfer of these CD4+ and CD8+ T cells and their progeny into yet another set of naïve mice also provided protective immunity. After primary and secondary serial transfers, these cells expanded in their new hosts, and upregulated both effector and memory phenotypes, indicating self-renewal and multipotency. These data together strongly suggest a role of host immunity in adoptive immunotherapy. Activation of host T cells plays a crucial role in generating effective anti-tumor responses in adoptive immunotherapeutic strategies.
Characteristics and outcomes of advanced gastric cancer patients treated with at least three lines of chemotherapy: analysis on 300 Italian real-world cases
Authors: G. Aprile, V. Fanotto, C. Vivaldi, C. Fontanella, R. Bordonaro, F. Leone, L. Rimassa, G. Rosati, G. Pasquini, G. Tomasello, L. Ferrari, D. Santini, R. Giampieri, F. Pietrantonio, S. Cordio, R. Filippi, S. Bozzarelli, C. Caparello, L. Fornaro
Journal: Annals of Oncology (2016)